Table 4.
Comparison of clinicopathological parameters against TRF2, Bcl-xL and p53 expressions
| TRF2 expression (n) OS (5 year,%) | Bcl-xL expression (n) OS (5 year,%) | p53 expression (n) OS (5 year,%) | ||||
|---|---|---|---|---|---|---|
| Stage (n) | High | Low | High | Low | High | Low |
| IIB (7) | 5 | 2 | 2 | 5 | 3 | 4 |
| n.d. | 50 | n.d. | 80 | 66.7 | n.d. | |
| IIIB-IVA (13) | 8 | 5 | 9 | 4 | 6 | 7 |
| 50 | 20 | 11 | n.d. | 16.7 | 57.1 | |
| P log rank | 0.04* | 0,006* | 0,01* | |||
| Histologic grade (n) | ||||||
| High grade (12) | 7 | 5 | 7 | 5 | 5 | 7 |
| 42 | 20 | 28** | 80 | 40** | 57.1 | |
| Low grade (8) | 6 | 2 | 4 | 4 | 4 | 4 |
| 83 | 50 | 75 | n.d. | 75 | n.d. | |
| P log rank | 0,14 | 0,01* | 0,01* | |||
*Correlation is significant at the 0.05 level (2-tailed); ** 3-year survival; n: number of patients; n.d.: not determined, all censored.